Supplementation of Cholecalciferol and Related Active Metabolites Through Bioenhancing Layer's Eggs (SCRAMBLE)

September 29, 2026 updated by: Cornell University

Biofortified Vitamin D Metabolites in Eggs and Their Impact on Vitamin D Status and the Gut Microbiome

The purpose of this research is to evaluate if 1) consumption of vitamin D3- or 25(OH)D3-biofortified eggs will increase vitamin D and 25(OH)D status in young adults who consume these bioenhanced eggs, 2) to determine if the gut microbiome profile is associated with 25(OH)D or vitamin D status and 3) to evaluate possible changes in the gut microbiome following an 8-week supplementation period providing 5(OH)D- or vitamin D bioenhanced eggs.

Study Overview

Detailed Description

In the wintertime, decreased UVB exposure limits vitamin D synthesis. Vitamin D insufficiency is common in the US and globally, with insufficiency evident in 41% of US adults over the age of 18 years, and has been linked to several adverse health outcomes. While dairy products are the major source of dietary vitamin D intake for the US public, little attention has been placed on other animal products (meat or eggs) as a source of vitamin D3 and 25(OH)D3. Determining the bioavailability of vitamin D-fortified eggs can inform updated dietary guidelines.

Decreased 25(OH)D status has also been associated with a less diverse gut microbiome. Additionally, little attention has been given to how bioenhanced foods containing vitamin D3 or 25(OH)D3 may differentially shape the gut microbiome and thus human vitamin D metabolism. Prior research shows a strong correlation between 1,25(OH)2D3 concentration and gut microbial diversity in elderly men. Further research will help inform recommendations that address the efficacy of the form of vitamin D ingested from food products and how vitamin D status may shape the gut microbiota.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kimberly O'Brien, PhD
  • Phone Number: (607) 255-3743
  • Email: koo4@cornell.edu

Study Locations

    • New York
      • Ithaca, New York, United States, 14850
        • Recruiting
        • Human Metabolic Research Unit
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adults
  • Non-smoking
  • Age between 18- 40 years
  • Females: premenopausal and not pregnant or lactating
  • Body mass index (BMI) between 18.5-27.0 kg/m2.
  • No planned trip(s) to lower latitudes during the 8-week study

Exclusion Criteria:

  • BMI <18.5 or > 27.0 kg/m2,
  • Age <18 y or > 40y,
  • Smoking
  • Pregnancy, lactating
  • Have gastrointestinal disorders/malabsorption diseases/dietary restrictions/use of medications known to impact vitamin D and 25(OH)D absorption
  • Been prescribed antibiotics within 3 months before enrolling
  • History or current diagnosis of any of the following conditions: intestinal problems (cystic fibrosis, Crohn's Disease, IBD, etc.), blood disorders (sickle cell, thalassemia, etc.), stomach problems (ulcers or other problems requiring antacids), joint diseases requiring anti-inflammatory medication, or asthma.
  • Planned trip(s) to lower latitudes during the 8-week study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vitamin D3 bioenhanced eggs

Six vitamin D3-fortified eggs per week will be provided to participants to consume each week for 8 weeks

Experimental: 25(OH)D3 bioenhanced eggs

Six 25(OH)D3-fortified eggs will per week be provided to participants to consume each week for 8 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vitamin D Status
Time Frame: Baseline, and time course of week 2, week 4, week 6, week 8

Serum concentrations of vitamin D2, vitamin D3, 25(OH)D2, 25(OH)D3, 1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D3, and vitamin D binding protein concentration will be measured biweekly over 8 weeks to assess vitamin D and 25(OH)D bioavailability.

Baseline, and time course of week 2, week 4, week 6, week 8
Gut microbiome composition
Time Frame: Baseline, week 4, week 8

Fecal samples will be collected for metagenomic analyses to evaluate the impact of vitamin D or 25(OH)D status and intake on the gut microbiome.

Baseline, week 4, week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

September 29, 2026

First Submitted That Met QC Criteria

September 29, 2026

First Posted (Actual)

October 5, 2026

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB0150561
  • 2026-67017-46090 (Other Grant/Funding Number: USDA)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe